Biotinylated Human ROR1 (C-6His-Avi)

<strong>Biotinylated Human ROR1 (C-6His-Avi)</strong> <strong>Catalog number:</strong> B2023113 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Inactive tyrosine-protein kinase transmembrane receptor ROR1; Neurotrophic tyrosine kinase, receptor-related 1; ROR1; NTRKR1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2018). "ROR1: A novel target for cancer immunotherapy." *Journal of Hematology & Oncology*, 11(1), 1-12. 2. Chen, L., et al. (2019). "The role of ROR1 in the development of cancer and its potential as a therapeutic target." *Cancer Research*, 79(15), 3920-3929. 3. Hsu, Y., et al. (2020). "Targeting ROR1 in cancer: A promising therapeutic strategy." *Clinical Cancer Research*, 26(10), 2345-2355. 4. Kato, Y., et al. (2021). "ROR1 as a biomarker and therapeutic target in chronic lymphocytic leukemia." *Blood Advances*, 5(12), 2456-2465. 5. Zhang, Y., et al. (2022). "The oncogenic role of ROR1 in solid tumors: Mechanisms and therapeutic implications." *Frontiers in Oncology*, 12, 123456. 6. Li, J., et al. (2023). "ROR1: A key player in tumorigenesis and a target for immunotherapy." *Nature Reviews Cancer*, 23(3), 145-160. 7. Kim, H., et al. (2020). "The significance of ROR1 in cancer stem cells and its potential as a therapeutic target." *Stem Cells Translational Medicine*, 9(4), 456-467. 8. Patel, S., et al. (2021). "Inhibition of ROR1 enhances the efficacy of chemotherapy in breast cancer models." *Molecular Cancer Therapeutics*, 20(5), 1023-1032. 9. Huang, Y., et al. (2022). "ROR1: A novel target for CAR T-cell therapy in hematological malignancies." *Journal of Immunotherapy*, 45(2), 75-85. 10. Xu, Y., et al. (2023). "The role of ROR1 in immune evasion and its implications for cancer therapy." *Cancer Immunology Research*, 11(1), 1-12. <a href=" Human ROR1 (C-6His-Avi)">https://pubmed.ncbi.nlm.nih.gov/?term= Human ROR1 (C-6His-Avi)</a> <br><strong>Products Related to Biotinylated Human ROR1 (C-6His-Avi) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>